Introduction
============

Cancer metastasis is responsible for more than 90% of cancer-related deaths [@B1]. In breast cancer, many noncoding RNAs are reported to be involved in lung metastasis. miRNA microarray profiling revealed that miR-374a was most strongly upregulated in lung metastatic derivatives of breast cancer cell lines and that miR-374a levels correlated with metastatic recurrence in breast cancer patients [@B2]. lncRNA MALAT1 was identified as a metastasis-suppressing lncRNA in breast cancer that was inversely correlated with breast cancer progression and metastatic ability [@B3]. However, the involvement of circular RNAs (circRNAs) in breast cancer lung metastasis remains unknown.

circRNAs are considered important regulators and biomarkers of cancer progression. Furthermore, circRNAs have been shown to function as miRNA sponges or competitive endogenous RNAs (ceRNAs) [@B4]. In triple negative breast cancer, circAGFG1 promoted cell proliferation, mobility and invasion by acting as a ceRNA of miR-195 to relieve the repression of cyclin E1 expression [@B5]. Moreover, circ_0006528 promoted breast cancer cell proliferation, invasion and migration by sponging miR-7 to promote the expression of Raf1 and activate the MAPK/ERK pathway [@B6]. All these studies suggest that circRNAs are potential therapeutic targets and prognostic predictors for breast cancer and deserve deeper exploration.

In this study, we performed high-throughput circular RNA microarray assays of primary breast cancer tissues and lung metastatic tissues to explore the potential involvement of circRNAs in breast cancer lung metastasis. Kaplan-Meier survival analysis and a series of experiments were conducted to analyze the clinical significance and functions of the selected circRNA in breast cancer. The regulatory effects and potential mechanisms of the selected circRNA on a miRNA and its target genes were further investigated.

Material and Methods
====================

Patient samples
---------------

Primary breast cancer tissues and lung metastatic tissues were collected from Nanhua Affiliated Hospital and subjected to circRNA microarray analysis. Breast cancer tissues from 150 patients were collected from Nanhua Affiliated Hospital and subjected to qRT-PCR. Patients who underwent curative surgical treatment (mastectomy or breast-conserving surgery with axillary evaluation) and did not receive any chemotherapy or radiation therapy beforehand were recruited. The exclusion criteria included male patients, inflammatory breast carcinomas, bilateral carcinomas, and history of any malignant tumor. The characteristics of the 150 breast cancer patients are summarized in Table [1](#T1){ref-type="table"}.

Microarray analysis
-------------------

CircRNA microarray analysis was performed with CapitalBio Technology Human CircRNA Array v2. Data were analyzed with GeneSpring software V13.0 (Agilent). The result was log2 transformed and median centered by genes with CLUSTER 3.0 software and analyzed by hierarchical clustering with average linkage.

Cell culture and transfection
-----------------------------

Breast cell lines were purchased from American Type Culture Collection (ATCC, USA). Cells were cultured according to the supplier\'s instructions. DNA fingerprinting was conducted to verify cell authenticity.

Cells were transfected using Lipofectamine 2000 (Invitrogen, USA). A vector overexpressing circNFIC, miR-658 mimics and inhibitors were purchased from GeneCopoeia.

Quantitative real-time PCR (qRT-PCR)
------------------------------------

RNA was isolated by TRIzol (Invitrogen). Nuclear and cytoplasmic fractions were isolated by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, USA). qRT-PCR was performed with SYBR Premix Ex Taq (Takara Bio Inc., China) and All-in-One™miRNA qRT-PCR Detection Kit (GeneCopoeia, USA). Primers were synthesized by Invitrogen ([Supplementary Table 1](#SM0){ref-type="supplementary-material"}).

Cell counting kit-8 (CCK-8) assay
---------------------------------

Cell proliferation was assessed by CCK-8 assay (Dojindo Laboratories, Japan). Cells (1×10^3^) were seeded into 96-well plates, and CCK-8 solution (10 μl) was added 48 h after transfection. After 2 h of incubation at 37 °C, the absorbance at 450 nM was measured in a microtiter plate reader (Bio-Tek EPOCH2, USA).

Colony formation assay
----------------------

Cells were seeded in 6-well plates at a density of 1×10^3^ cells/well and incubated at 37 °C for 2 weeks. Colonies were fixed in methanol, stained with 0.1% crystal violet, imaged and counted.

Mouse xenograft model
---------------------

Cells (2×10^6^) were subcutaneously injected into the dorsal flanks of 4-week-old female BALB/c nude mice (three mice per group), and the mice were then treated with an intratumoral injection (40 μL NC or circNFIC) every 4 days. Xenografts were excised under anesthesia after 4 weeks, and the tumor weights were measured.

For lung metastasis studies, 1 × 10^5^ cells were injected into the tail veins of mice (three mice per group). After 8 weeks, the lungs were excised under anesthesia, and the numbers of macroscopically visible lung metastatic nodules were counted and validated by assessment of hematoxylin and eosin (HE)-stained sections by microscopy.

Luciferase reporter assay
-------------------------

Cells (5×10^3^) were seeded and cotransfected with the corresponding plasmids and miR-658 mimics using Lipofectamine 2000. After 48 h of incubation, luciferase activities were quantified with a Dual-Luciferase Reporter Assay System (Promega, USA).

RNA immunoprecipitation (RIP) assay
-----------------------------------

Cells were cotransfected with MS2bs-circNFIC, MS2bs-circNFIC-mt or blank control MS2bs-Rluc together with MS2bp-GFP using Lipofectamine 2000. After 48 h, RIP was performed with a GFP antibody (Roche, USA) and a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA). The RNA complexes were then purified, and the level of miR-660 was quantified.

For the RIP assay for Ago2, 48 h after transfection, RIP was performed with an anti-Ago2 antibody (Millipore), and the levels of circNFIC, UPK1A and miR-658 were measured.

Statistical analysis
--------------------

Comparisons between groups were analyzed using t tests. Kaplan-Meier plots and log-rank tests were used for the survival analysis. Unless otherwise indicated, the data are presented as the mean ± S.D. of three independent experiments. *P* \< 0.05 was considered statistically significant. The statistical analysis was performed using SPSS 19.0 software.

Results
=======

circNFIC is downregulated in breast cancer and correlated with poor outcome
---------------------------------------------------------------------------

To investigate the potential involvement of circRNAs in breast cancer metastasis to the lung, we performed high-throughput circular RNA microarray assays of primary breast cancer tissues and lung metastatic tissues. Hierarchical clustering showed the top 20 upregulated and downregulated circRNAs based on fold change ≥ 2 (Figure [1](#F1){ref-type="fig"}A). Reactome pathway analysis of the linear mRNA transcripts corresponding to the circRNAs revealed that the corresponding linear mRNAs were related to cell cycle pathways (Figure [1](#F1){ref-type="fig"}B). Moreover, GO analysis showed that the corresponding linear mRNAs were related to cell cycle progression, indicating their potential involvement in cancer progression (Figure [1](#F1){ref-type="fig"}C). Among the top 20 downregulated circRNAs, hsa_circ_0002018 decreased the most in lung metastatic tissues; therefore, we decided to study this circRNA. Hsa_circ_0002018 (chr19: 3449011-3452664) was predicted to derive from nuclear factor I C (NFIC) by the human reference genome (GRCh37/hg19). Thus, we named hsa_circ_0002018 \"circNFIC\".

We measured circNFIC expression in breast cancer cell lines and found that circNFIC was downregulated in breast cancer cell lines, especially in MDA-MB-468 and MDA-MB-231 cells (Figure [1](#F1){ref-type="fig"}D). Therefore, we used these cell lines in the following study. To explore the clinical significance of circNFIC in breast cancer, we performed survival analysis on 150 breast cancer patients. The characteristics of these patients are summarized in Table [1](#T1){ref-type="table"}. Patients with circNFIC expression equal to or greater than the average were assigned to the "circNFIC high" group. We explored the potential clinicopathological implications of circNFIC in breast cancer. We found that low levels of circNFIC were related to shorter overall survival and lymph node metastasis (*P* = 0.002 and 0.021, respectively). Kaplan-Meier survival analysis revealed that low levels of circNFIC were related to poor outcome of breast cancer, indicating the vital role circNFIC plays in breast cancer progression (Figure [1](#F1){ref-type="fig"}E).

Overexpressing circNFIC suppresses the proliferation and migration of breast cancer cells
-----------------------------------------------------------------------------------------

To explore the function of circNFIC in breast cancer, we overexpressed circNFIC in breast cancer cell lines (Figure [2](#F2){ref-type="fig"}A). The CCK-8 assay showed that circNFIC overexpression significantly suppressed cell proliferation (Figure [2](#F2){ref-type="fig"}B). circNFIC overexpression also reduced the colony formation ability of breast cancer cells (Figure [2](#F2){ref-type="fig"}C).

To further explore the function of circNFIC *in vivo*, mouse xenograft models were established. The results showed that circNFIC overexpression significantly decreased tumor growth (Figure [2](#F2){ref-type="fig"}D) and lung metastasis (Figure [2](#F2){ref-type="fig"}E), indicating that circNFIC overexpression suppresses cell proliferation and migration in breast cancer.

circNFIC acts as a sponge for miR-658
-------------------------------------

Next, we detected the intracellular location of circNFIC and found that circNFIC predominantly localized in the cytoplasm, indicating that circNFIC might function as a miRNA sponge (Figure [3](#F3){ref-type="fig"}A). Therefore, we used Circular RNA Interactome (<https://circinteractome.nia.nih.gov/index.html>) to predict the potential circRNA/miRNA interactions, and binding sites for miR-658 were found within the circNFIC sequence (Figure [3](#F3){ref-type="fig"}B). We then detected the expression of miR-658 in breast cancer cell lines and found that miR-658 was upregulated (Figure [3](#F3){ref-type="fig"}C). A luciferase reporter assay showed that the luciferase activity was reduced after cotransfection of the wild-type luciferase reporter and miR-658 mimics, while the mutated luciferase reporter exerted no such effect (Figure [3](#F3){ref-type="fig"}D). To confirm the direct binding of circNFIC and miR-658, a RIP assay was performed. The results showed that miR-658 was predominantly enriched in RNAs retrieved from MS2bs-circNFIC, indicating that circNFIC directly interacts with miR-658 and could act as a sponge for miR-658 (Figure [3](#F3){ref-type="fig"}E).

circNFIC acts as a ceRNA to regulate UPK1A
------------------------------------------

To validate whether circNFIC sponges miR-658 and restores the expression of its target, we searched TargetScan for potential target genes of miR-658, and Uroplakin 1A (UPK1A) was predicted (Figure [4](#F4){ref-type="fig"}A). Thus, we explored UPK1A expression in breast cancer cell lines and found that UPK1A was downregulated (Figure [4](#F4){ref-type="fig"}B). A luciferase reporter assay revealed decreased luciferase activity after cotransfection of miR-658 mimics and the wild-type luciferase reporter, while the mutated luciferase reporter exerted no such effect (Figure [4](#F4){ref-type="fig"}C). Furthermore, miR-658 suppressed UPK1A expression, while the miR-658 inhibitor increased UPK1A expression, indicating that UPK1A is a target gene of miR-658 and could be regulated by miR-658 (Figure [4](#F4){ref-type="fig"}D & [4](#F4){ref-type="fig"}E).

Next, a RIP assay on Ago2 showed that circNFIC, UPK1A and miR-658 were mainly enriched in Ago2-bound transcripts, indicating that circNFIC and UPK1A are recruited to an Ago2-related RISC where they interact with miR-658 (Figure [4](#F4){ref-type="fig"}F). Additionally, overexpressing circNFIC increased the enrichment of circNFIC on Ago2 but decreased the enrichment of UPK1A on Ago2, indicating that circNFIC could function as a ceRNA and compete with UPK1A to bind the miRNA (Figure [4](#F4){ref-type="fig"}G). Furthermore, circNFIC overexpression led to increased UPK1A expression, while miR-658 reversed this increase, indicating that circNFIC sponges miR-658 to regulate UPK1A expression (Figure [4](#F4){ref-type="fig"}H).

Discussion
==========

Metastasis accounts for approximately 90% of cancer patient deaths [@B7]. Noncoding RNAs have been reported to be critical for the metastatic ability of cancer cells and therefore have been considered potential therapeutic targets [@B8]. In breast cancer, ectopic miR-126 expression significantly suppressed the formation of lung metastases, while suppressing miR-126 significantly increased the ability of breast cancer cells to metastasize to the lung [@B9]. For circRNAs, circANKS1B was found to be upregulated in triple-negative breast cancer and could promote breast cancer invasion and metastasis by inducing epithelial-to-mesenchymal transition [@B10], demonstrating that circRNAs could be therapeutic targets to better prevent breast cancer metastasis.

In this study, we performed high-throughput circular RNA microarray assays of primary breast cancer tissues and lung metastatic tissues and found that circNFIC (hsa_circ_0002018) was the most downregulated circRNA in lung metastatic tissues. In addition, circNFIC was confirmed to be downregulated in breast cancer cell lines. Moreover, low levels of circNFIC were related to poor outcome of breast cancer, indicating the vital role circNFIC plays in breast cancer progression. We further overexpressed circNFIC in breast cancer cell lines and found that circNFIC overexpression significantly suppressed cell proliferation and lung metastasis.

It has been reported that circRNAs could serve as ceRNAs to regulate cancer progression via competitive binding to shared miRNAs [@B11]. In breast cancer, circIRAK3 sponged miR-3607 to regulate the expression of forkhead box C1 and further mediated breast cancer cell migration [@B12]. circTADA2A-E6 suppressed breast cancer cell proliferation, migration, invasion and clonogenicity by acting as a miR-203a-3p sponge to restore the expression of SOCS3 [@B13]. Furthermore, hsa_circ_0072995 regulated breast cancer invasion and migration by sponging miR-30c-2-3p [@B14]. Here, a mechanistic study revealed that circNFIC could also act as a sponge for miR-658 to regulate breast cancer progression.

miR-658 was found to be highly expressed in gastric cancer tissues and cells [@B15]. Elevated circulating miR-658 was associated with tumor metastasis through activation of the PAX3-MET pathway [@B16]. Here, we found that miR-658 was upregulated in breast cancer cell lines, and circNFIC could directly interact with miR-658 and act as a sponge for miR-658 to regulate the expression of UPK1A, a target gene of miR-658.

UPK1A has long been reported to be a tumor suppressor gene in multiple cancers and could be a useful marker for diagnosis and prognostic prediction. In esophageal squamous cell carcinoma, UPK1A was found to be downregulated, and UPK1A could inhibit cell proliferation, clonogenicity, cell motility and tumor formation [@B17]. In gastric cancer, UPK1A was reported to be downregulated, and increased expression of UPK1A could inhibit cell migration and invasion [@B18]. In colorectal cancer, UPK1A was also downregulated, and low expression of UPK1A was significantly associated with poorer survival [@B19]. Here, we found that UPK1A was downregulated in breast cancer cell lines and that circNFIC could sponge miR-658 to regulate the expression of UPK1A and the progression of breast cancer.

Taken together, our study indicates that circNFIC is downregulated in breast cancer and is related to poor outcome. Overexpression of circNFIC inhibits cell proliferation and migration in breast cancer. Moreover, circNFIC functions as a ceRNA to regulate UPK1A expression by decoying miR-658. circNFIC can be used as a diagnostic biomarker and therapeutic target for breast cancer.

Conclusions
===========

circNFIC could be used as a promising prognostic biomarker for breast cancer patients, and therapeutic targeting of the circNFIC/miR-658/UPK1A network may be a potential strategy for the treatment of breast cancer.
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![**circNFIC is downregulated in breast cancer and is correlated with poor outcome A.** Hierarchical cluster analysis showing the top 20 upregulated and downregulated circRNAs in lung metastatic tissues compared with primary breast cancer tissues: red, upregulated; blue, downregulated. **B.** Reactome pathway analysis was performed. **C.** GO analysis was performed. **D.** The expression of circNFIC in breast cancer cell lines. **E.** OS curves for 150 breast cancer patients with high or low circNFIC expression.](jcav11p4222g001){#F1}

![**Overexpressing circNFIC suppresses the proliferation and migration of breast cancer cells A.** circNFIC was successfully overexpressed in breast cancer cell lines. **B.** CCK-8 assay was performed to assess cell proliferation. **C.** Colony formation assay was performed to assess cell colony-forming ability (left), and the colony formation number was quantified by ImageJ (right). **D.** Representative images of mouse xenograft tumors (left) and tumor weights are summarized (right).**E.** Representative images of lung metastatic nodules in HE-stained sections (left). The number of metastatic nodules was quantified (right). \**P* \< 0.05, \*\**P* \< 0.01](jcav11p4222g002){#F2}

![**circNFIC acts as a sponge for miR-658 A.** The levels of nuclear control transcript (18S), cytoplasmic control transcript (GAPDH) and circNFIC were assessed in nuclear and cytoplasmic fractions. **B.** The predicted binding sites of miR-658 within the circNFIC sequence. **C.** The expression of miR-658 in breast cancer cell lines. **D.** Luciferase assay of cells cotransfected with miR-658 mimics and wild-type or mutant luciferase reporter. **E.** MS2-based RIP assay in cells transfected with MS2bs-circNFIC, MS2bs-circNFIC-mt or control. \*\**P* \< 0.01](jcav11p4222g003){#F3}

![**circNFIC acts as a ceRNA to regulate UPK1A A.** The predicted binding sites of miR-658 within the UPK1A 3\'UTR. **B.** The expression of UPK1A in breast cancer cell lines. **C.** Cells were transfected, and a luciferase assay was performed. **D.** Cells were transfected, and the expression of UPK1A was detected. **E.** The expression of UPK1A was detected. **F.** RIP assay showing the enrichment of circNFIC, UPK1A and miR-658 in the Ago2 fraction relative to the IgG fraction. **G.** Cells were transfected, and a RIP assay on Ago2 was performed. **H.** Cells were transfected, and the expression of UPK1A was detected. \*\**P* \< 0.01](jcav11p4222g004){#F4}

###### 

Clinicopathological variables and circNFIC expression in 150 breast cancer patients

  Characteristics       Total (n=150)   circNFIC high (n=57)   circNFIC low (n=93)   *P* value          
  --------------------- --------------- ---------------------- --------------------- ----------- ------ -------------
  OS                                                                                                    **0.002\***
  Present               104             48                     46.2                  56          53.8   
  Absent                46              9                      19.6                  37          80.4   
  Age (years)                                                                                           0.515
  \<50                  66              27                     40.9                  39          59.1   
  ≥50                   84              30                     35.7                  54          64.3   
  Tumor size (cm)\*\*                                                                                   0.473
  ≤2                    34              11                     32.4                  23          67.6   
  \>2                   115             45                     39.1                  70          60.9   
  LNMET\*\*                                                                                             **0.021\***
  Yes                   91              28                     30.8                  63          69.2   
  No                    54              27                     50.0                  27          50.0   
  TNM stage\*\*                                                                                         0.182
  I-II                  97              40                     41.2                  57          58.8   
  III- IV               50              15                     30.0                  35          70.0   
  ER status\*\*                                                                                         0.059
  Positive              93              41                     44.1                  52          55.9   
  Negative              50              14                     28.0                  36          72.0   
  PR status\*\*                                                                                         0.324
  Positive              81              34                     42.0                  47          58.0   
  Negative              62              21                     33.9                  41          66.1   
  HER-2 status\*\*                                                                                      0.689
  Positive              41              17                     41.5                  24          58.5   
  Negative              103             39                     37.9                  64          62.1   

\* indicates statistical significance (*P* \< 0.05).

\% indicates percentage within the row.

\*\* The case number does not add up to the total in several categories because a few patients were excluded from those categories.
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